Evidence map›Paper›PMID 29746857›Full record

ArticleThe Journal of urology2018

Women Undergoing Third Line Overactive Bladder Treatment Demonstrate Elevated Thermal Temporal Summation.

W Stuart Reynolds, Casey Kowalik, Joshua Cohn, Melissa Kaufman, Alan Wein, Roger Dmochowski, Stephen Bruehl

Open access · greenAbstract readComparative Study
In one paragraph

Article in The Journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

W Stuart ReynoldsDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: w.stuart.reynolds@vumc.org.
Casey KowalikDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Joshua CohnDepartment of Urology, Einstein Healthcare Network, Pennsylvania.
Melissa KaufmanDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Alan WeinDivision of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Roger DmochowskiDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Stephen BruehlDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt University Medical Center · USEinstein Healthcare Network · USUniversity of Pennsylvania · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Afferent Hyperactivity Mechanisms in Overactive Bladder SyndromeK23DK103910 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI REYNOLDS, WILLIAM STUART · 2015 to 2019
$737k
NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NIDDK NIH HHS K23 DK103910
6 · The paper itself

Abstract

purposeWe sought to determine whether women with overactive bladder who required third line therapy would demonstrate greater central sensitization, indexed by temporal summation to heat pain stimuli, than those with overactive bladder. MATERIALS AND

methodsWe recruited 39 women with overactive bladder from the urology clinic who were planning to undergo interventional therapy for medication refractory overactive bladder with onabotulinumtoxinA bladder injection or sacral neuromodulation. We also recruited 55 women with overactive bladder who were newly seen at our urology clinic or who responded to advertisements for study participation. Participants underwent quantitative sensory testing using a thermal temporal summation protocol. The primary study outcome was the degree of temporal summation as reflected in the magnitude of positive slope of the line fit to the series of 10 stimuli at a 49C target temperature. We compared the degree of temporal summation between the study groups using linear regression.

resultsWomen in the group undergoing third line therapy showed significantly higher standardized temporal summation slopes than those in the nontreatment group (β = 1.57, 95% CI 0.18-2.96, t = 2.25, p = 0.027). On exploratory analyses a history of incontinence surgery or hysterectomy was associated with significantly greater temporal summation.

conclusionsIn this study the degree of temporal summation was elevated in women undergoing third line overactive bladder therapy compared to women with overactive bladder who were not undergoing that therapy. These findings suggest there may be pathophysiological differences, specifically in afferent nerve function and processing, in some women with overactive bladder.

Indexed as

Pain PerceptionAdultAgedBotulinum Toxins, Type ACentral Nervous System SensitizationCohort StudiesFemaleFollow-Up StudiesHot TemperatureHumansLinear ModelsLumbosacral PlexusMiddle AgedRetrospective StudiesRisk AssessmentSeverity of Illness IndexBotulinum Toxins, Type Acentral nervous system sensitizationoveractivepatient reported outcome measurespostsynaptic potential summationurgeurinary bladderurinary incontinence

Identifiers

PMID29746857
PMCPMC6146049
OpenAlexW2802941813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.